Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)

Boehringer Ingelheim Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)

Docket		Date Filed	2023-06-23
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To
Patents	10,034,877; 9,486,526
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Apotex Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2023-12-20	31	Redacted Document	U.S. Patent Nos. 9,486,526 (“the 526 patent”) and 10,034,877 (“the 877 patent”) (“the patents-in-suit… that the claims of the 526 patent are infringed. All of the 526 patent’s claims recite a method for …CONFIDENTIAL—FILED UNDER SEAL 877 patent are infringed. All of the 877 patent’s claims require treating a patient…claimed uses of the patents-in-suit. “To prevail on a theory of induced patent infringement, a plaintiff… or patients, to infringe the patent by using the drug for the patented use. Warner-Lambert, 316 F.3d	External link to document
2024-01-31	43	Redacted Document	The patents asserted in this action are: U.S. Patent Nos. 9,486,526 (“the ’526 Patent”) and 10,034,877…adjustment. See D.I. 2, Ex. 1 (’526 Patent), Ex. 2 (’877 Patent). …manner that infringes the Asserted Patents. In the context of patents for methods of treatment involving…many other claims of the Asserted Patents, claim 13 of the ’877 patent recites a method for treating T2DM….5 C. Tradjenta® and the Asserted Patents ...............................................	External link to document